Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vasculitis | 2 | 2018 | 51 | 0.870 |
Why?
|
| Paraneoplastic Syndromes, Nervous System | 1 | 2020 | 1 | 0.690 |
Why?
|
| ELAV Proteins | 1 | 2020 | 1 | 0.690 |
Why?
|
| Leprosy | 2 | 2014 | 7 | 0.680 |
Why?
|
| Antibodies, Antinuclear | 1 | 2020 | 36 | 0.670 |
Why?
|
| Mononeuropathies | 2 | 2018 | 5 | 0.670 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 56 | 0.660 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 42 | 0.650 |
Why?
|
| Autoantigens | 1 | 2020 | 125 | 0.640 |
Why?
|
| Minocycline | 1 | 2018 | 25 | 0.600 |
Why?
|
| Polyneuropathies | 2 | 2009 | 10 | 0.570 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2016 | 2049 | 0.560 |
Why?
|
| Lipodystrophy | 1 | 2016 | 11 | 0.530 |
Why?
|
| Subcutaneous Fat | 1 | 2016 | 47 | 0.510 |
Why?
|
| Neuromuscular Diseases | 3 | 2018 | 23 | 0.470 |
Why?
|
| Sural Nerve | 1 | 2014 | 2 | 0.450 |
Why?
|
| Neuroma | 1 | 2014 | 2 | 0.450 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2011 | 60 | 0.440 |
Why?
|
| Gelsolin | 1 | 2013 | 5 | 0.430 |
Why?
|
| Facial Paralysis | 1 | 2013 | 12 | 0.420 |
Why?
|
| Sciatic Neuropathy | 2 | 2011 | 3 | 0.400 |
Why?
|
| Amyloidosis | 1 | 2013 | 60 | 0.400 |
Why?
|
| Dermatomyositis | 1 | 2011 | 6 | 0.390 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 737 | 0.390 |
Why?
|
| Mycophenolic Acid | 1 | 2011 | 32 | 0.390 |
Why?
|
| Neural Conduction | 5 | 2018 | 28 | 0.380 |
Why?
|
| Meningism | 1 | 2011 | 2 | 0.380 |
Why?
|
| Neck Muscles | 1 | 2011 | 9 | 0.370 |
Why?
|
| Tendinopathy | 1 | 2011 | 10 | 0.370 |
Why?
|
| Reflex, Abnormal | 1 | 2010 | 3 | 0.360 |
Why?
|
| Baroreflex | 1 | 2010 | 18 | 0.350 |
Why?
|
| Meningitis | 1 | 2010 | 18 | 0.350 |
Why?
|
| Radiation Injuries | 1 | 2010 | 62 | 0.340 |
Why?
|
| Autoimmune Diseases | 1 | 2011 | 224 | 0.330 |
Why?
|
| Sensation Disorders | 1 | 2009 | 21 | 0.320 |
Why?
|
| Angina, Unstable | 1 | 2009 | 57 | 0.320 |
Why?
|
| Paclitaxel | 1 | 2009 | 91 | 0.310 |
Why?
|
| Drug-Eluting Stents | 1 | 2009 | 54 | 0.310 |
Why?
|
| Brain Abscess | 1 | 2008 | 7 | 0.300 |
Why?
|
| Cerebellar Ataxia | 1 | 2008 | 13 | 0.300 |
Why?
|
| Meningococcal Infections | 1 | 2008 | 27 | 0.300 |
Why?
|
| Histoplasmosis | 1 | 2008 | 23 | 0.300 |
Why?
|
| Triazoles | 1 | 2008 | 52 | 0.300 |
Why?
|
| Thromboembolism | 1 | 2008 | 71 | 0.290 |
Why?
|
| Pyrimidines | 1 | 2008 | 124 | 0.280 |
Why?
|
| Electrodiagnosis | 2 | 2004 | 14 | 0.270 |
Why?
|
| Unnecessary Procedures | 1 | 2006 | 42 | 0.260 |
Why?
|
| Neurosurgical Procedures | 1 | 2006 | 94 | 0.250 |
Why?
|
| Polyradiculoneuropathy | 1 | 2005 | 1 | 0.250 |
Why?
|
| Diagnostic Errors | 1 | 2006 | 98 | 0.250 |
Why?
|
| Myelin-Associated Glycoprotein | 1 | 2005 | 12 | 0.250 |
Why?
|
| Myelin Sheath | 1 | 2005 | 36 | 0.250 |
Why?
|
| Humans | 20 | 2025 | 60142 | 0.240 |
Why?
|
| Peripheral Nervous System | 1 | 2004 | 9 | 0.240 |
Why?
|
| Water Pollutants, Chemical | 1 | 2025 | 40 | 0.240 |
Why?
|
| Male | 14 | 2025 | 27975 | 0.230 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2004 | 27 | 0.230 |
Why?
|
| Autoantibodies | 1 | 2005 | 175 | 0.230 |
Why?
|
| Nervous System Diseases | 1 | 2025 | 105 | 0.220 |
Why?
|
| Environmental Exposure | 1 | 2025 | 212 | 0.210 |
Why?
|
| Middle Aged | 8 | 2025 | 16539 | 0.210 |
Why?
|
| Peripheral Nerves | 2 | 2018 | 30 | 0.210 |
Why?
|
| Diagnosis, Differential | 3 | 2016 | 910 | 0.200 |
Why?
|
| Adult | 7 | 2025 | 15988 | 0.200 |
Why?
|
| Treatment Outcome | 4 | 2020 | 5263 | 0.200 |
Why?
|
| Female | 11 | 2025 | 31253 | 0.190 |
Why?
|
| Electromyography | 4 | 2018 | 87 | 0.190 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2006 | 477 | 0.190 |
Why?
|
| Aged | 7 | 2025 | 13584 | 0.170 |
Why?
|
| Antibodies, Neoplasm | 1 | 2020 | 27 | 0.170 |
Why?
|
| Etoposide | 1 | 2020 | 35 | 0.170 |
Why?
|
| Cerebellar Neoplasms | 1 | 2020 | 9 | 0.170 |
Why?
|
| Carboplatin | 1 | 2020 | 40 | 0.170 |
Why?
|
| Carcinoma, Small Cell | 1 | 2020 | 21 | 0.170 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 61 | 0.170 |
Why?
|
| Muscle, Skeletal | 2 | 2018 | 678 | 0.160 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 361 | 0.160 |
Why?
|
| Rituximab | 2 | 2011 | 82 | 0.150 |
Why?
|
| Biopsy | 2 | 2018 | 376 | 0.150 |
Why?
|
| Prednisone | 1 | 2018 | 80 | 0.150 |
Why?
|
| Leg | 2 | 2008 | 84 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 405 | 0.130 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 161 | 0.130 |
Why?
|
| Disease Progression | 1 | 2020 | 1054 | 0.120 |
Why?
|
| Anxiety | 1 | 2018 | 400 | 0.120 |
Why?
|
| Lambert-Eaton Myasthenic Syndrome | 1 | 2013 | 1 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 577 | 0.110 |
Why?
|
| Diabetes Complications | 1 | 2013 | 102 | 0.100 |
Why?
|
| Phenotype | 1 | 2016 | 1157 | 0.100 |
Why?
|
| Hashimoto Disease | 1 | 2011 | 1 | 0.100 |
Why?
|
| Dermatologic Agents | 1 | 2011 | 21 | 0.100 |
Why?
|
| Neuroimaging | 1 | 2013 | 131 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 435 | 0.090 |
Why?
|
| Muscular Diseases | 1 | 2010 | 47 | 0.080 |
Why?
|
| Paresthesia | 1 | 2009 | 4 | 0.080 |
Why?
|
| Coronary Restenosis | 1 | 2009 | 19 | 0.080 |
Why?
|
| Antirheumatic Agents | 1 | 2011 | 214 | 0.080 |
Why?
|
| Sjogren's Syndrome | 1 | 2009 | 26 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 1 | 2010 | 153 | 0.080 |
Why?
|
| Immune System | 1 | 2010 | 129 | 0.080 |
Why?
|
| Angioplasty, Balloon | 1 | 2009 | 58 | 0.080 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2008 | 1 | 0.080 |
Why?
|
| Disease Susceptibility | 1 | 2009 | 157 | 0.080 |
Why?
|
| Umbilical Arteries | 1 | 2008 | 9 | 0.080 |
Why?
|
| Voriconazole | 1 | 2008 | 6 | 0.080 |
Why?
|
| Liver Abscess | 1 | 2008 | 18 | 0.080 |
Why?
|
| Itraconazole | 1 | 2008 | 13 | 0.080 |
Why?
|
| Arm | 1 | 2008 | 38 | 0.080 |
Why?
|
| Bone Marrow Diseases | 1 | 2008 | 14 | 0.080 |
Why?
|
| Arteriovenous Malformations | 1 | 2008 | 42 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2010 | 239 | 0.070 |
Why?
|
| Pediatrics | 1 | 2011 | 268 | 0.070 |
Why?
|
| Frontal Lobe | 1 | 2008 | 66 | 0.070 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2011 | 325 | 0.070 |
Why?
|
| Catheterization | 1 | 2008 | 111 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 213 | 0.070 |
Why?
|
| Blood Pressure | 1 | 2010 | 522 | 0.070 |
Why?
|
| Cerebellum | 1 | 2008 | 94 | 0.070 |
Why?
|
| Antifungal Agents | 1 | 2008 | 117 | 0.070 |
Why?
|
| Bacteremia | 1 | 2008 | 93 | 0.070 |
Why?
|
| Recurrence | 1 | 2009 | 600 | 0.070 |
Why?
|
| Arthropathy, Neurogenic | 1 | 2006 | 5 | 0.070 |
Why?
|
| Radiculopathy | 1 | 2006 | 20 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2006 | 90 | 0.060 |
Why?
|
| Spinal Cord Diseases | 1 | 2006 | 39 | 0.060 |
Why?
|
| Child | 3 | 2013 | 4335 | 0.060 |
Why?
|
| Hypesthesia | 1 | 2005 | 8 | 0.060 |
Why?
|
| Gait Ataxia | 1 | 2005 | 3 | 0.060 |
Why?
|
| Siblings | 1 | 2005 | 45 | 0.060 |
Why?
|
| Leprostatic Agents | 1 | 2004 | 3 | 0.060 |
Why?
|
| Embolization, Therapeutic | 1 | 2008 | 309 | 0.060 |
Why?
|
| Mobility Limitation | 1 | 2025 | 55 | 0.060 |
Why?
|
| Mutation | 1 | 2013 | 2471 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 2005 | 99 | 0.060 |
Why?
|
| Age Factors | 1 | 2008 | 1525 | 0.060 |
Why?
|
| Disability Evaluation | 1 | 2005 | 217 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 1481 | 0.050 |
Why?
|
| Recovery of Function | 1 | 2005 | 267 | 0.050 |
Why?
|
| Nerve Fibers | 1 | 2003 | 29 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2008 | 1850 | 0.050 |
Why?
|
| Muscles | 1 | 2003 | 171 | 0.050 |
Why?
|
| Motor Neurons | 1 | 2003 | 206 | 0.050 |
Why?
|
| Adolescent | 2 | 2011 | 5957 | 0.050 |
Why?
|
| Prevalence | 1 | 2025 | 1300 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 858 | 0.040 |
Why?
|
| Neoplasms | 1 | 2011 | 1261 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2010 | 5197 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2010 | 6140 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 2505 | 0.040 |
Why?
|
| HIV Infections | 1 | 2004 | 927 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2018 | 387 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1237 | 0.030 |
Why?
|
| United States | 1 | 2025 | 7622 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 3131 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2616 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 2010 | 41 | 0.020 |
Why?
|
| Muscle Weakness | 1 | 2010 | 29 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 2010 | 38 | 0.020 |
Why?
|
| Necrosis | 1 | 2010 | 140 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 4396 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 304 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 2362 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2010 | 237 | 0.020 |
Why?
|
| Animals | 1 | 2004 | 19771 | 0.020 |
Why?
|
| Infant | 1 | 2011 | 1530 | 0.020 |
Why?
|